Page last updated: 2024-11-03

rabeprazole and Pyrosis

rabeprazole has been researched along with Pyrosis in 39 studies

Rabeprazole: A 4-(3-methoxypropoxy)-3-methylpyridinyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.

Research Excerpts

ExcerptRelevanceReference
"This systematic review and network meta-analysis aimed to assess the relative efficacy of vonoprazan and proton pump inhibitors (PPIs) on early heartburn symptom resolution in patients with erosive esophagitis."9.22Network Meta-analysis Comparing Vonoprazan and Proton Pump Inhibitors for Heartburn Symptoms in Erosive Esophagitis. ( Deguchi, H; Fernandez, J; Fujimori, I; Igarashi, A; Nakano, H; Oshima, T, 2022)
"Patients with LA grade C or D oesophagitis were randomised to rabeprazole-ER 50 mg or esomeprazole 40 mg once daily in two identical 8-week double-blind trials (N = 2130)."9.15Randomised clinical trial: a novel rabeprazole extended release 50 mg formulation vs. esomeprazole 40 mg in healing of moderate-to-severe erosive oesophagitis - the results of two double-blind studies. ( Chou, C; Goldstein, MJ; Ibegbu, I; Johnson, DA; Katz, PO; Laine, L; Lu, Y; Rossiter, G, 2011)
"The primary efficacy end point, mean percentage of heartburn-free days, was significantly greater with rabeprazole vs."9.14Clinical trial: maintenance intermittent therapy with rabeprazole 20 mg in patients with symptomatic gastro-oesophageal reflux disease - a double-blind, placebo-controlled, randomized study. ( Delemos, B; Fass, R; Kao, R; Lu, Y; Nazareno, L; Xiang, J, 2010)
"Rabeprazole 20 mg was non-inferior to esomeprazole 40 mg for complete resolution of regurgitation and satisfactory resolution of heartburn and regurgitation."9.14Clinical trial: the treatment of gastro-oesophageal reflux disease in primary care--prospective randomized comparison of rabeprazole 20 mg with esomeprazole 20 and 40 mg. ( Eggleston, A; Holtmann, G; Katelaris, PH; Nandurkar, S; Thorpe, P, 2009)
"In GERD patients with nocturnal heartburn, rabeprazole 20 mg was significantly more effective than pantoprazole 40 mg in percentage time with intragastric pH >4 during the nighttime, daytime, and 24-h periods."9.14Effects of a single dose of rabeprazole 20 mg and pantoprazole 40 mg on 24-h intragastric acidity and oesophageal acid exposure: a randomized study in gastro-oesophageal reflux disease patients with a history of nocturnal heartburn. ( Delemos, B; Ieni, J; Lococo, J; Miner, P; Xiang, J, 2010)
"In GERD patients with nocturnal heartburn, a single oral dose of rabeprazole 20 mg increased intragastric pH more than pantoprazole 40 mg did throughout the 24 h after dosing."9.12Pharmacodynamic effects of single doses of rabeprazole 20 mg and pantoprazole 40 mg in patients with GERD and nocturnal heartburn. ( Baisley, K; Boyce, M; Delemos, B; Lee, D; Lomax, K; Morocutti, A; Warrington, S, 2007)
"This randomized, open-label study enrolled 331 GERD (heartburn-predominant) patients with a pre-existing proton pump inhibitor history of one month or longer, to an acute four-week trial with 20 mg rabeprazole daily for heartburn management."9.12Maintenance treatment of gastroesophageal reflux disease: an evaluation of continuous and on-demand therapy with rabeprazole 20 mg. ( Camacho, F; Dinniwell, J; Horbay, GL; Husein-Bhabha, FA; Morgan, DG; O'Mahony, MF; O'Mahony, WF; Roy, J, 2007)
" The numbers of patients with relief from heartburn on day 4 were similar in the two groups (84% for rabeprazole; 95% confidence interval, 76-90%; 83% for omeprazole; 95% confidence interval, 75-89%)."9.10A randomized, double-blind, comparative study of standard-dose rabeprazole and high-dose omeprazole in gastro-oesophageal reflux disease. ( Blum, AL; Bytzer, P; Holtmann, G; Loeffler, V; Metz, M, 2002)
"Rabeprazole was superior to ranitidine in esophageal healing and symptom relief in patients with erosive gastroesophageal reflux disease, and was equally well tolerated."9.09Rabeprazole versus ranitidine for the treatment of erosive gastroesophageal reflux disease: a double-blind, randomized clinical trial. Raberprazole Study Group. ( Farley, A; Humphries, TJ; Wruble, LD, 2000)
" These data suggest that administration of a PPI before the evening meal maximizes acid control and would be the preferred dosing schedule in GERD patients, particularly those with nocturnal symptoms."6.71Comparison of morning and evening administration of rabeprazole for gastro-oesophageal reflux and nocturnal gastric acid breakthrough in patients with reflux disease: a double-blind, cross-over study. ( McCallum, RW; Olyaee, M; Pehlivanov, ND; Sarosiek, I, 2003)
"Rabeprazole 10 mg/day was administered for 4 weeks to 180 patients who kept symptom diaries."5.34Efficacy of rabeprazole on heartburn symptom resolution in patients with non-erosive and erosive gastro-oesophageal reflux disease: a multicenter study from Japan. ( Chiba, T; Fujiwara, Y; Furuta, T; Habu, Y; Hongo, M; Ito, M; Kinoshita, Y; Koike, T; Miwa, H; Nagahara, A; Sasaki, M; Wada, T, 2007)
"This systematic review and network meta-analysis aimed to assess the relative efficacy of vonoprazan and proton pump inhibitors (PPIs) on early heartburn symptom resolution in patients with erosive esophagitis."5.22Network Meta-analysis Comparing Vonoprazan and Proton Pump Inhibitors for Heartburn Symptoms in Erosive Esophagitis. ( Deguchi, H; Fernandez, J; Fujimori, I; Igarashi, A; Nakano, H; Oshima, T, 2022)
"Complete heartburn relief rates were 21% in placebo, 34% in rabeprazole 5 mg and 44% in rabeprazole 10 mg (5 mg vs."5.15Randomised clinical trial: a multicentre, double-blind, placebo-controlled study on the efficacy and safety of rabeprazole 5 mg or 10 mg once daily in patients with non-erosive reflux disease. ( Ashida, K; Hongo, M; Kinoshita, Y, 2011)
"Patients with LA grade C or D oesophagitis were randomised to rabeprazole-ER 50 mg or esomeprazole 40 mg once daily in two identical 8-week double-blind trials (N = 2130)."5.15Randomised clinical trial: a novel rabeprazole extended release 50 mg formulation vs. esomeprazole 40 mg in healing of moderate-to-severe erosive oesophagitis - the results of two double-blind studies. ( Chou, C; Goldstein, MJ; Ibegbu, I; Johnson, DA; Katz, PO; Laine, L; Lu, Y; Rossiter, G, 2011)
"Administration of 5 mg and 10 mg rabeprazole sufficiently inhibited pathological gastroesophageal acid reflux and relieved heartburn episodes in NERD patients who did not respond to an antacid."5.15Acid-suppressive effect of rabeprazole 5 mg and 10 mg once daily by 24-hour esophageal pH monitoring in patients with non-erosive reflux disease in Japan: a multicenter, randomized, parallel-group, double-blind pharmacodynamic study. ( Ashida, K; Hongo, M; Kinoshita, Y, 2011)
"Patients with symptomatic gastroesophageal reflux disease (GERD) (NERD and RE) were treated with rabeprazole (RPZ) 10 mg once daily for 4 weeks."5.15Investigation of pretreatment prediction of proton pump inhibitor (PPI)-resistant patients with gastroesophageal reflux disease and the dose escalation challenge of PPIs-TORNADO study: a multicenter prospective study by the Acid-Related Symptom Research G ( Chiba, T; Fujiwara, Y; Furuta, T; Hongo, M; Ishihara, S; Kinoshita, Y; Koike, T; Kusano, M; Shimatani, T; Sugimoto, M, 2011)
"The primary efficacy end point, mean percentage of heartburn-free days, was significantly greater with rabeprazole vs."5.14Clinical trial: maintenance intermittent therapy with rabeprazole 20 mg in patients with symptomatic gastro-oesophageal reflux disease - a double-blind, placebo-controlled, randomized study. ( Delemos, B; Fass, R; Kao, R; Lu, Y; Nazareno, L; Xiang, J, 2010)
"In GERD patients with nocturnal heartburn, rabeprazole 20 mg was significantly more effective than pantoprazole 40 mg in percentage time with intragastric pH >4 during the nighttime, daytime, and 24-h periods."5.14Effects of a single dose of rabeprazole 20 mg and pantoprazole 40 mg on 24-h intragastric acidity and oesophageal acid exposure: a randomized study in gastro-oesophageal reflux disease patients with a history of nocturnal heartburn. ( Delemos, B; Ieni, J; Lococo, J; Miner, P; Xiang, J, 2010)
"In patients with endoscopy-confirmed erosive esophagitis treated with once-daily rabeprazole 20 mg, prompt and continuing improvements were seen in daytime and nighttime heartburn, belching, regurgitation, and dysphagia."5.14Rabeprazole 20 mg for erosive esophagitis-associated symptoms in a large, community-based study: additional results. ( Cutler, A; Delemos, B; Murthy, A; Robinson, M, 2010)
"Rabeprazole 20 mg was non-inferior to esomeprazole 40 mg for complete resolution of regurgitation and satisfactory resolution of heartburn and regurgitation."5.14Clinical trial: the treatment of gastro-oesophageal reflux disease in primary care--prospective randomized comparison of rabeprazole 20 mg with esomeprazole 20 and 40 mg. ( Eggleston, A; Holtmann, G; Katelaris, PH; Nandurkar, S; Thorpe, P, 2009)
"In GERD patients with nocturnal heartburn, a single oral dose of rabeprazole 20 mg increased intragastric pH more than pantoprazole 40 mg did throughout the 24 h after dosing."5.12Pharmacodynamic effects of single doses of rabeprazole 20 mg and pantoprazole 40 mg in patients with GERD and nocturnal heartburn. ( Baisley, K; Boyce, M; Delemos, B; Lee, D; Lomax, K; Morocutti, A; Warrington, S, 2007)
"This randomized, open-label study enrolled 331 GERD (heartburn-predominant) patients with a pre-existing proton pump inhibitor history of one month or longer, to an acute four-week trial with 20 mg rabeprazole daily for heartburn management."5.12Maintenance treatment of gastroesophageal reflux disease: an evaluation of continuous and on-demand therapy with rabeprazole 20 mg. ( Camacho, F; Dinniwell, J; Horbay, GL; Husein-Bhabha, FA; Morgan, DG; O'Mahony, MF; O'Mahony, WF; Roy, J, 2007)
"Oesophageal pH and heartburn severity were determined in 27 GERD subjects at baseline and on days 1, 2 and 8 of treatment with 20 mg omeprazole or 20 mg rabeprazole in a randomized, two-way crossover fashion."5.10Heartburn severity can predict pathologic oesophageal reflux in gastro-oesophageal reflux disease patients treated with a proton-pump inhibitor. ( Gardner, JD; Miner, PB; Robinson, M; Sloan, S, 2003)
"The mean heartburn score in patients administered rabeprazole decreased more rapidly than those given the other PPI."5.10Symptom relief in patients with reflux esophagitis: comparative study of omeprazole, lansoprazole, and rabeprazole. ( Adachi, K; Fujishiro, H; Hamamoto, N; Hashimoto, T; Hattori, S; Hirakawa, K; Kaji, T; Katsube, T; Kinoshita, Y; Komazawa, Y; Mihara, T; Miyake, T; Niigaki, M; Ono, M; Shizuku, T; Suetsugu, H; Taniura, H; Yagi, J; Yamamoto, S, 2003)
"On day 1, rabeprazole significantly decreased daytime and night-time heartburn severity, regurgitation and belching."5.10Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis. ( Fitzgerald, S; Hegedus, R; Jokubaitis, L; Murthy, A; Robinson, M, 2002)
" The numbers of patients with relief from heartburn on day 4 were similar in the two groups (84% for rabeprazole; 95% confidence interval, 76-90%; 83% for omeprazole; 95% confidence interval, 75-89%)."5.10A randomized, double-blind, comparative study of standard-dose rabeprazole and high-dose omeprazole in gastro-oesophageal reflux disease. ( Blum, AL; Bytzer, P; Holtmann, G; Loeffler, V; Metz, M, 2002)
"Rabeprazole was superior to ranitidine in esophageal healing and symptom relief in patients with erosive gastroesophageal reflux disease, and was equally well tolerated."5.09Rabeprazole versus ranitidine for the treatment of erosive gastroesophageal reflux disease: a double-blind, randomized clinical trial. Raberprazole Study Group. ( Farley, A; Humphries, TJ; Wruble, LD, 2000)
"The standard-dose esomeprazole 40 mg had more superiority in mucosal erosion healing and heartburn relief."4.95Comparative effectiveness and acceptability of the FDA-licensed proton pump inhibitors for erosive esophagitis: A PRISMA-compliant network meta-analysis. ( Li, MJ; Li, Q; Liu, LQ; Sun, M, 2017)
"The extraesophageal manifestations of gastroesophageal reflux disease (GERD) are more difficult to manage than the typical symptoms."2.94Efficacy of a high-dose proton pump inhibitor in patients with gastroesophageal reflux disease: a single center, randomized, open-label trial. ( Cho, JH; Kim, N; Lee, DH; Park, YS; Shin, CM; Yoon, H, 2020)
"Rabeprazole has a comparable efficacy compared to ranitidine when given on-demand for the treatment of NERD."2.77A randomized open-label trial of on-demand rabeprazole vs ranitidine for patients with non-erosive reflux disease. ( Aswad, R; El-Samad, S; Haddad, R; Hashash, JG; Jamali, FR; Kobeissy, AA; Ladki, R; Skoury, AM; Soweid, AM, 2012)
" Fifteen healthy Japanese volunteers are dosed for 7 days in a 5-way randomly crossover trial: placebo, aspirin 100 mg, rabeprazole 10 mg, and aspirin 100 mg plus rabeprazole 10 mg either once daily or 4 times per day."2.75Esophageal mucosal injury with low-dose aspirin and its prevention by rabeprazole. ( Furuta, T; Hishida, A; Ikuma, M; Kodaira, C; Nishino, M; Sugimoto, M; Sugimura, H; Tanaka, T; Yamade, M, 2010)
" These data suggest that administration of a PPI before the evening meal maximizes acid control and would be the preferred dosing schedule in GERD patients, particularly those with nocturnal symptoms."2.71Comparison of morning and evening administration of rabeprazole for gastro-oesophageal reflux and nocturnal gastric acid breakthrough in patients with reflux disease: a double-blind, cross-over study. ( McCallum, RW; Olyaee, M; Pehlivanov, ND; Sarosiek, I, 2003)
"Heartburn was a poor predictor of whether patients with chest pain were GORD-positive or GORD-negative by objective testing."2.47Response of unexplained chest pain to proton pump inhibitor treatment in patients with and without objective evidence of gastro-oesophageal reflux disease. ( Howden, CW; Hughes, N; Kahrilas, PJ, 2011)
"Whether these patients are part of the GERD spectrum or have another diagnosis is not clear."2.43Review article: the role of acid suppression in patients with non-erosive reflux disease or functional heartburn. ( DeVault, KR, 2006)
"Symptom eradication in patients with Barrett's esophagus (BE) does not guarantee control of acid or duodenogastroesophageal reflux (DGER)."1.42Control of acid and duodenogastroesophageal reflux (DGER) in patients with Barrett's esophagus. ( Bhat, YM; Falk, GW; Maqbool, S; Richter, JE; Vaezi, MF; Yachimski, P, 2015)
"To clarify the pathogenesis of gastroesophageal reflux disease symptoms in non-erosive reflux disease (NERD) patients."1.42Characteristics of symptomatic reflux episodes in Japanese proton pump inhibitor-refractory non-erosive reflux disease patients. ( Ara, N; Asano, N; Hatta, W; Iijima, K; Kikuchi, H; Koike, T; Nakagawa, K; Saito, M; Shimosegawa, T; Uno, K, 2015)
"Japanese GERD patients are often obese, as reported previously, but some GERD patients are underweight."1.38Symptoms and quality of life in underweight gastroesophageal reflux disease patients and therapeutic responses to proton pump inhibitors. ( Hongo, M; Kusano, M; Miwa, H, 2012)
"Of 132 GERD patients enrolled, 101 completed the study."1.35The influence of co-morbid IBS and psychological distress on outcomes and quality of life following PPI therapy in patients with gastro-oesophageal reflux disease. ( Adlis, SA; Chey, WD; Nojkov, B; Rai, J; Rubenstein, JH; Saad, R; Shaw, MJ; Weinman, B, 2008)
"Rabeprazole 10 mg/day was administered for 4 weeks to 180 patients who kept symptom diaries."1.34Efficacy of rabeprazole on heartburn symptom resolution in patients with non-erosive and erosive gastro-oesophageal reflux disease: a multicenter study from Japan. ( Chiba, T; Fujiwara, Y; Furuta, T; Habu, Y; Hongo, M; Ito, M; Kinoshita, Y; Koike, T; Miwa, H; Nagahara, A; Sasaki, M; Wada, T, 2007)

Research

Studies (39)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's19 (48.72)29.6817
2010's17 (43.59)24.3611
2020's3 (7.69)2.80

Authors

AuthorsStudies
Oshima, T1
Igarashi, A1
Nakano, H1
Deguchi, H1
Fujimori, I1
Fernandez, J1
Barberio, B1
Visaggi, P1
Savarino, E2
de Bortoli, N1
Black, CJ1
Ford, AC1
Cho, JH1
Shin, CM1
Yoon, H1
Park, YS1
Kim, N1
Lee, DH1
Li, MJ1
Li, Q1
Sun, M1
Liu, LQ1
Yachimski, P1
Maqbool, S1
Bhat, YM1
Richter, JE1
Falk, GW1
Vaezi, MF1
Nakagawa, K1
Koike, T3
Iijima, K1
Saito, M1
Kikuchi, H1
Hatta, W1
Ara, N1
Uno, K1
Asano, N1
Shimosegawa, T1
Eggleston, A1
Katelaris, PH1
Nandurkar, S1
Thorpe, P1
Holtmann, G2
Cutler, A1
Robinson, M3
Murthy, A2
Delemos, B4
Sugimoto, M3
Nishino, M2
Kodaira, C1
Yamade, M1
Ikuma, M1
Tanaka, T1
Sugimura, H1
Hishida, A1
Furuta, T3
Miner, P1
Xiang, J2
Lococo, J1
Ieni, J1
Fass, R1
Nazareno, L1
Kao, R1
Lu, Y2
Iwakiri, K1
Sano, H1
Tanaka, Y1
Kawami, N1
Umezawa, M1
Futagami, S1
Hoshihara, Y1
Nomura, T1
Miyashita, M1
Sakamoto, C1
Kinoshita, Y6
Ashida, K2
Hongo, M6
Laine, L1
Katz, PO1
Johnson, DA1
Ibegbu, I1
Goldstein, MJ1
Chou, C1
Rossiter, G1
Kahrilas, PJ1
Hughes, N1
Howden, CW1
Wang, AJ1
Liang, MJ1
Jiang, AY1
Lin, JK1
Xiao, YL1
Peng, S1
Chen, J1
Wen, WP1
Chen, MH1
Shimatani, T2
Ishihara, S1
Fujiwara, Y2
Kusano, M2
Chiba, T3
Adachi, K2
Furuta, K1
Ito, M2
Kurosawa, S1
Manabe, N1
Mannen, K1
Miwa, H2
Kobeissy, AA1
Hashash, JG1
Jamali, FR1
Skoury, AM1
Haddad, R1
El-Samad, S1
Ladki, R1
Aswad, R1
Soweid, AM1
Laheij, RJ1
Van Rossum, LG1
Jansen, JB1
Verheugt, FW1
Gardner, JD1
Sloan, S1
Miner, PB2
Pehlivanov, ND1
Olyaee, M1
Sarosiek, I1
McCallum, RW1
Hashimoto, T1
Hamamoto, N1
Hirakawa, K1
Niigaki, M1
Miyake, T1
Taniura, H1
Ono, M1
Kaji, T1
Suetsugu, H1
Yagi, J1
Komazawa, Y1
Mihara, T1
Katsube, T1
Fujishiro, H1
Shizuku, T1
Hattori, S1
Yamamoto, S1
Bytzer, P2
Blum, A1
De Herdt, D1
Dubois, D1
Zentilin, P1
Accornero, L1
Dulbecco, P1
Savarino, V1
Inamori, M1
Togawa, J1
Iwasaki, T1
Ozawa, Y1
Kikuchi, T1
Muramatsu, K1
Chiguchi, G1
Matsumoto, S1
Kawamura, H1
Abe, Y1
Kirikoshi, H1
Kobayashi, N1
Shimamura, T1
Kubota, K1
Sakaguchi, T1
Saito, S1
Ueno, N1
Nakajima, A1
Tsuji, S1
Kawano, S1
Pace, F1
Annese, V1
Prada, A1
Zambelli, A1
Casalini, S1
Nardini, P1
Bianchi Porro, G1
DeVault, KR1
Rodriguez-Stanley, S1
Bemben, D1
Zubaidi, S1
Redinger, N1
Warrington, S1
Baisley, K1
Lee, D1
Lomax, K1
Boyce, M1
Morocutti, A1
Sasaki, M1
Habu, Y1
Wada, T1
Nagahara, A1
Morgan, DG1
O'Mahony, MF1
O'Mahony, WF1
Roy, J1
Camacho, F1
Dinniwell, J1
Horbay, GL1
Husein-Bhabha, FA1
Nojkov, B1
Rubenstein, JH1
Adlis, SA1
Shaw, MJ1
Saad, R1
Rai, J1
Weinman, B1
Chey, WD1
Farley, A1
Wruble, LD1
Humphries, TJ1
Fitzgerald, S1
Hegedus, R1
Jokubaitis, L1
Metz, M1
Loeffler, V1
Blum, AL1

Clinical Trials (8)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Treatment Response of High-dose and Standard-dose Rabeprazole for Gastroesophageal Reflux Disease With Extra-esophageal Manifestations: a Single-center, Randomized, Open-label Trial.[NCT04001400]Phase 373 participants (Actual)Interventional2012-10-10Completed
The Rabeprazole and Esomeprazole Reflux Assessment Trial (TREAT)[NCT00464308]Phase 41,392 participants (Actual)Interventional2006-11-30Completed
A Randomized, Two-way Crossover Study of the Effects of a Single Dose of Rabeprazole or Pantoprazole on 24-hour Intragastric Acidity and Esophageal Acid Exposure in GERD Patients With a History of Nocturnal Heartburn[NCT00237367]Phase 452 participants (Actual)InterventionalCompleted
A Double-Blind, Placebo-Controlled Study of Rabeprazole 20 mg Maintenance Intermittent Therapy Following Acute Treatment in Patients Wth Symptomatic Gastroesophageal Reflux Disease[NCT00165841]Phase 2200 participants (Actual)Interventional2004-10-31Completed
A Randomized Double-Blind Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)[NCT00658528]Phase 31,061 participants (Actual)Interventional2008-02-29Completed
A Randomized, Double-Blind, Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)[NCT00658775]Phase 31,069 participants (Actual)Interventional2008-02-29Completed
"Double-Blind Placebo-Controlled Randomized Withdrawal Trial Assessing the Efficacy and Tolerability of On-Demand Maintenance Therapy With 10mg o.d. Rabeprazole for 6 Months in Non-Erosive Reflux Disease Patients With Complete Symptom Relief After 4 Week [NCT00236392]Phase 3422 participants (Actual)Interventional2001-10-31Completed
Comparing Omeprazole With Fluoxetine for Treatment of Non Erosive Reflux Disease and Its Subgroups: a Double-blind Placebo-controlled Clinical Trial[NCT01269788]Phase 2/Phase 3144 participants (Actual)Interventional2010-08-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

The Mean Percentage of Participants With 24-hour Heartburn Symptom Free Periods

(NCT00464308)
Timeframe: 4 weeks

Interventionpercent of participants (Mean)
Rabeprazole 20 mg/Day56.3
Esomeprazole 40 mg/Day63.4
Esomeprazole 20 mg/Day56.1

The Median Time to Complete Relief of Regurgitation Symptoms

(NCT00464308)
Timeframe: 4 weeks

Interventiondays (Median)
Rabeprazole 20 mg/Day9
Esomeprazole 40 mg/Day11
Esomeprazole 20 mg/Day13

The Median Time to Complete Resolution of Heartburn Symptoms.

(NCT00464308)
Timeframe: week 4 of treatment

Interventiondays (Median)
Rabeprazole 20 mg/Day11
Esomeprazole 40 mg/Day9
Esomeprazole 20 mg/Day12

The Number of Patients Achieving Complete Resolution of Regurgitation Symptoms at Week 4

Complete resolution is the absence of symptoms for any 7 consecutive days within the 4 week period assessed by the PAGI-SYM scale. This likert scale describes various symptoms as follows: 0-none, 1-Very Mild, 2-Mild, 3-Moderate, 4-Severe, 5-Very Severe. (NCT00464308)
Timeframe: 4 weeks

Interventionparticipants (Number)
Rabeprazole 20 mg/Day281
Esomeprazole 40 mg/Day283
Esomeprazole 20 mg/Day276

The Number of Patients Achieving Satisfactory Resolution of Heartburn by Week 4

Satisfactory resolution, which is achieved if, on any 7 consecutive days within the 4 week period, the severity of symptoms never exceeds 'mild' (symptoms must be absent, very mild, or mild) assessed by the PAGI-SYM scale. This likert scale describes various symptoms as follows: 0-none, 1-Very Mild, 2-Mild, 3-Moderate, 4-Severe, 5-Very Severe. (NCT00464308)
Timeframe: 4 weeks

Interventionparticipants (Number)
Rabeprazole 20 mg/Day405
Esomeprazole 40 mg/Day418
Esomeprazole 20 mg/Day414

The Number of Patients Achieving Satisfactory Resolution of Regurgitation Symptoms by Week 4

Satisfactory resolution, which is achieved if, on any 7 consecutive days within the 4 week period, the severity of symptoms never exceeds 'mild' (symptoms must be absent, very mild, or mild)assessed by the PAGI-SYM scale. This likert scale describes a series of symptoms as follows: 0-None, 1-Very Mild, 2-Mild, 3-Moderate, 4-Severe, 5 Very Severe. (NCT00464308)
Timeframe: 4 weeks

Interventionparticipants (Number)
Rabeprazole 20 mg/Day397
Esomeprazole 40 mg/Day413
Esomeprazole 20 mg/Day402

The Number of Patients With Complete Resolution of Heartburn by Week 4

Complete resolution is the absence of symptoms for any 7 consecutive days within the 4 week period assessed by the PAGI-SYM scale. This likert scale describes a series of symptoms as follows: 0-None, 1-Very Mild, 2-Mild, 3-Moderate, 4-Severe, 5 Very Severe. (NCT00464308)
Timeframe: week 4 of treatment

Interventionparticipants (Number)
Rabeprazole 20 mg/Day272
Esomeprazole 40 mg/Day302
Esomeprazole 20 mg/Day278

The Percentage of Heartburn-free Days (24-hour Periods) During the 6-month Maintenance Treatment Phase (ITT Population).

The percentage of heartburn-free days during the 6-month Maintenance Treatment Phase in patients treated with rabeprazole 20 mg compared to patients who received placebo in the ITT Population. Heartburn-free day was defined as no heartburn in both the daytime and nighttime period on a given day. Note a total 388 subjects were enrolled at the beginning of Acute Phase and 200 subjects were enrolled into the double-blind 6-month maintenance treatment phase. (NCT00165841)
Timeframe: 6 months double-blind maintenance phase

InterventionPercentage of Days (Mean)
Rabeprazole 20 mg82.58
Placebo62.17

Percentage of Participants Who Achieved Diary-recorded Sustained Resolution of Heartburn by Week 4

During the first 4 weeks of the Double-blind Phase, participants were to record heartburn in a daily diary. Participant daily symptoms for the assessment of hearburn was based on a commonly used 4-point Likert scale of none, mild, moderate and severe. A participant was considered achieving sustained resolution of heartburn if the participant had maintained at least 7 consecutive heartburn-free days. (NCT00658528)
Timeframe: Week 4

,
InterventionPercentage of Participants (Number)
YesNoMissing
ESO 40 mg48.246.35.5
RAB ER 50 mg48.344.37.4

Percentage of Participants With eGERD Who Achieved Endoscopically-confirmed Healing by 4 Weeks

"Healing at week 4 or 8 were based on improvement of eGERD of the LA classification of esophagitis Grade C or D from Baseline. Classifications include:~Not Present: No breaks (erosions) in the esophageal mucosa (however, edema, erythema, or friability may be present).~Grade A: One or more mucosal breaks not more than 5 mm in maximum length. Grade B: One or more mucosal breaks more than 5 mm in maximum length, but not continuous between the tops of 2 mucosal folds.~Grade C: Mucosal breaks continuous between the tops of 2 or more mucosal folds, but involving less than 75% of the esophageal circumference.~Grade D: Mucosal breaks involving at least 75% of the esophageal circumference." (NCT00658528)
Timeframe: Baseline and Week 4

,
InterventionPercentage of Participants (Number)
YesNoMissing
ESO 40 mg50.347.81.9
RAB ER 50 mg54.842.62.7

Percentage of Participants With Erosive Gastroesophageal Reflux Disease (eGERD) Who Achieved Endoscopically-confirmed Healing by 8 Weeks

"Healing at week 4 or 8 were based on improvement of eGERD of the Los Angeles (LA) classification of esophagitis Grade C or D from Baseline. Classifications include:~Not Present: No breaks (erosions) in the esophageal mucosa (however, edema, erythema, or friability may be present).~Grade A: One or more mucosal breaks not more than 5 mm in maximum length. Grade B: One or more mucosal breaks more than 5 mm in maximum length, but not continuous between the tops of 2 mucosal folds.~Grade C: Mucosal breaks continuous between the tops of 2 or more mucosal folds, but involving less than 75% of the esophageal circumference.~Gread D: Mucosal breaks involving at least 75% of the esophageal circumference." (NCT00658528)
Timeframe: Baseline and Week 8

,
InterventionPercentage of Participants (Number)
YesNoMissing
ESO 40 mg7520.34.7
RAB ER 50 mg8014.95.2

Percentage of Participants Who Achieved Diary-recorded Sustained Resolution of Heartburn by Week 4

During the first 4 weeks of the Double-blind Phase, participants were to record heartburn in a daily diary. Participant daily symptoms for the assessment of heartburn was based on a commonly used 4-point Likert scale of none, mild, moderate and severe. A participant was considered achieving sustained resolution of heartburn if the participant had maintained at least 7 consecutive heartburn-free days. (NCT00658775)
Timeframe: Week 4

,
InterventionPercentage of Participants (Number)
YesNoMissing
ESO 40mg52.5407.4
RAB ER 50mg53.239.67.2

Percentage of Participants With eGERD Who Achieved Endoscopically-confirmed Healing by 4 Weeks

"Healing at week 4 or 8 were based on improvement of eGERD of the LA classification of esophagitis Grade C or D from Baseline. Classifications include:~Not Present: No breaks (erosions) in the esophageal mucosa (however, edema, erythema, or friability may be present) Grade A: One or more mucosal breaks not more than 5mm in maximum length. Grade B: One or more mucosal breaks more than 5mm in maximum length, but not continuous between the tops of 2 mucosal folds.~Grade C: Mucosal breaks continuous between the tops of 2 or more mucosal folds, but involving less than 75% of the esophageal circumference.~Grade D: Mucosal breaks involving at least 75% of the esophageal circumference." (NCT00658775)
Timeframe: Baseline and Week 4

,
InterventionPercentage of Participants (Number)
YesNoMissing
ESO 40mg50.746.43
RAB ER 50mg50.9472.1

Percentage of Participants With Erosive Gastroesophageal Reflux Disease (eGERD) Who Achieved Endoscopically-confirmed Healing by 8 Weeks

"Healing at week 4 or 8 were based on improvement of eGERD of the Los Angeles (LA) classification of esophagitis Grade C or D from Baseline. Classifications include:~Not Present: No breaks (erosions) in the esophageal mucosa (however, edema, erythema, or friability may be present) Grade A: One or more mucosal breaks not more than 5mm in maximum length. Grade B: One or more mucosal breaks more than 5mm in maximum length, but not continuous between the tops of 2 mucosal folds.~Grade C: Mucosal breaks continuous between the tops of 2 or more mucosal folds, but involving less than 75% of the esophageal circumference.~Grade D: Mucosal breaks involving at least 75% of the esophageal circumference." (NCT00658775)
Timeframe: Baseline and Week 8

,
InterventionPercentage of Participants (Number)
YesNoMissing
ESO 40mg78.416.65
RAB ER 50mg77.518.44.2

Reviews

5 reviews available for rabeprazole and Pyrosis

ArticleYear
Network Meta-analysis Comparing Vonoprazan and Proton Pump Inhibitors for Heartburn Symptoms in Erosive Esophagitis.
    Journal of clinical gastroenterology, 2022, 07-01, Volume: 56, Issue:6

    Topics: Adult; Bayes Theorem; Esophagitis; Gastroesophageal Reflux; Heartburn; Humans; Network Meta-Analysis

2022
Comparison of acid-lowering drugs for endoscopy negative reflux disease: Systematic review and network Meta-Analysis.
    Neurogastroenterology and motility, 2023, Volume: 35, Issue:1

    Topics: Adult; Alginates; Dexlansoprazole; Endoscopy, Gastrointestinal; Gastroesophageal Reflux; Gastrointes

2023
Comparative effectiveness and acceptability of the FDA-licensed proton pump inhibitors for erosive esophagitis: A PRISMA-compliant network meta-analysis.
    Medicine, 2017, Volume: 96, Issue:39

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Comparative Effectiveness Research; Dexlansoprazole;

2017
Response of unexplained chest pain to proton pump inhibitor treatment in patients with and without objective evidence of gastro-oesophageal reflux disease.
    Gut, 2011, Volume: 60, Issue:11

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Chest Pain; Esophagus; Gastroesophageal Reflux; Heartburn;

2011
Review article: the role of acid suppression in patients with non-erosive reflux disease or functional heartburn.
    Alimentary pharmacology & therapeutics, 2006, Volume: 23 Suppl 1

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Endoscopy, Digestive Sys

2006

Trials

25 trials available for rabeprazole and Pyrosis

ArticleYear
Efficacy of a high-dose proton pump inhibitor in patients with gastroesophageal reflux disease: a single center, randomized, open-label trial.
    BMC gastroenterology, 2020, Aug-18, Volume: 20, Issue:1

    Topics: Gastroesophageal Reflux; Heartburn; Humans; Proton Pump Inhibitors; Rabeprazole; Treatment Outcome

2020
Clinical trial: the treatment of gastro-oesophageal reflux disease in primary care--prospective randomized comparison of rabeprazole 20 mg with esomeprazole 20 and 40 mg.
    Alimentary pharmacology & therapeutics, 2009, May-01, Volume: 29, Issue:9

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agen

2009
Rabeprazole 20 mg for erosive esophagitis-associated symptoms in a large, community-based study: additional results.
    Digestive diseases and sciences, 2010, Volume: 55, Issue:2

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Dose-Response Relationship, Drug; Endoscopy, Gastroin

2010
Esophageal mucosal injury with low-dose aspirin and its prevention by rabeprazole.
    Journal of clinical pharmacology, 2010, Volume: 50, Issue:3

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Anti-Inflammatory Agents, Non-Steroid

2010
Effects of a single dose of rabeprazole 20 mg and pantoprazole 40 mg on 24-h intragastric acidity and oesophageal acid exposure: a randomized study in gastro-oesophageal reflux disease patients with a history of nocturnal heartburn.
    Alimentary pharmacology & therapeutics, 2010, Volume: 31, Issue:9

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Cross-Over Stud

2010
Clinical trial: maintenance intermittent therapy with rabeprazole 20 mg in patients with symptomatic gastro-oesophageal reflux disease - a double-blind, placebo-controlled, randomized study.
    Alimentary pharmacology & therapeutics, 2010, Volume: 31, Issue:9

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Dose-Response R

2010
Randomised clinical trial: a multicentre, double-blind, placebo-controlled study on the efficacy and safety of rabeprazole 5 mg or 10 mg once daily in patients with non-erosive reflux disease.
    Alimentary pharmacology & therapeutics, 2011, Volume: 33, Issue:2

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Dose-Response Relationship,

2011
Randomised clinical trial: a novel rabeprazole extended release 50 mg formulation vs. esomeprazole 40 mg in healing of moderate-to-severe erosive oesophagitis - the results of two double-blind studies.
    Alimentary pharmacology & therapeutics, 2011, Volume: 33, Issue:2

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Double-Blind Method; Esomeprazole;

2011
Randomised clinical trial: a novel rabeprazole extended release 50 mg formulation vs. esomeprazole 40 mg in healing of moderate-to-severe erosive oesophagitis - the results of two double-blind studies.
    Alimentary pharmacology & therapeutics, 2011, Volume: 33, Issue:2

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Double-Blind Method; Esomeprazole;

2011
Randomised clinical trial: a novel rabeprazole extended release 50 mg formulation vs. esomeprazole 40 mg in healing of moderate-to-severe erosive oesophagitis - the results of two double-blind studies.
    Alimentary pharmacology & therapeutics, 2011, Volume: 33, Issue:2

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Double-Blind Method; Esomeprazole;

2011
Randomised clinical trial: a novel rabeprazole extended release 50 mg formulation vs. esomeprazole 40 mg in healing of moderate-to-severe erosive oesophagitis - the results of two double-blind studies.
    Alimentary pharmacology & therapeutics, 2011, Volume: 33, Issue:2

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Double-Blind Method; Esomeprazole;

2011
Acid-suppressive effect of rabeprazole 5 mg and 10 mg once daily by 24-hour esophageal pH monitoring in patients with non-erosive reflux disease in Japan: a multicenter, randomized, parallel-group, double-blind pharmacodynamic study.
    Digestive diseases and sciences, 2011, Volume: 56, Issue:8

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Esophageal pH Monitoring; Female;

2011
Investigation of pretreatment prediction of proton pump inhibitor (PPI)-resistant patients with gastroesophageal reflux disease and the dose escalation challenge of PPIs-TORNADO study: a multicenter prospective study by the Acid-Related Symptom Research G
    Journal of gastroenterology, 2011, Volume: 46, Issue:11

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Dose-Response Relationship, Drug;

2011
Predicting the efficacy of proton pump inhibitors in patients with non-erosive reflux disease before therapy using dual-channel 24-h esophageal pH monitoring.
    Journal of gastroenterology and hepatology, 2012, Volume: 27, Issue:5

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Chi-Square Distribution; Esophageal pH M

2012
A randomized open-label trial of on-demand rabeprazole vs ranitidine for patients with non-erosive reflux disease.
    World journal of gastroenterology, 2012, May-21, Volume: 18, Issue:19

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Female; Gastroesophageal Reflux; Heartburn; Histamin

2012
Proton-pump inhibitor therapy for acetylsalicylic acid associated upper gastrointestinal symptoms: a randomized placebo-controlled trial.
    Alimentary pharmacology & therapeutics, 2003, Jul-01, Volume: 18, Issue:1

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents;

2003
Heartburn severity can predict pathologic oesophageal reflux in gastro-oesophageal reflux disease patients treated with a proton-pump inhibitor.
    Alimentary pharmacology & therapeutics, 2003, Jul-01, Volume: 18, Issue:1

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles;

2003
Comparison of morning and evening administration of rabeprazole for gastro-oesophageal reflux and nocturnal gastric acid breakthrough in patients with reflux disease: a double-blind, cross-over study.
    Alimentary pharmacology & therapeutics, 2003, Nov-01, Volume: 18, Issue:9

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Circadian Rhythm; Cross-

2003
Symptom relief in patients with reflux esophagitis: comparative study of omeprazole, lansoprazole, and rabeprazole.
    Journal of gastroenterology and hepatology, 2003, Volume: 18, Issue:12

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Benzimid

2003
Six-month trial of on-demand rabeprazole 10 mg maintains symptom relief in patients with non-erosive reflux disease.
    Alimentary pharmacology & therapeutics, 2004, Jul-15, Volume: 20, Issue:2

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Double-Blin

2004
Early effects of lafutidine or rabeprazole on intragastric acidity: which drug is more suitable for on-demand use?
    Journal of gastroenterology, 2005, Volume: 40, Issue:5

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acetamides; Administration, Oral; Adult; Benzimidazoles; Cr

2005
Rabeprazole is equivalent to omeprazole in the treatment of erosive gastro-oesophageal reflux disease. A randomised, double-blind, comparative study of rabeprazole and omeprazole 20 mg in acute treatment of reflux oesophagitis, followed by a maintenance o
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2005, Volume: 37, Issue:10

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Antacids; Anti-Ulcer Agents; Benzimidazoles; Dose-Re

2005
Effect of esophageal acid and prophylactic rabeprazole on performance in runners.
    Medicine and science in sports and exercise, 2006, Volume: 38, Issue:9

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Esophagus; Exercise Test; Female;

2006
Pharmacodynamic effects of single doses of rabeprazole 20 mg and pantoprazole 40 mg in patients with GERD and nocturnal heartburn.
    Alimentary pharmacology & therapeutics, 2007, Feb-15, Volume: 25, Issue:4

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Cross-Over Stud

2007
Maintenance treatment of gastroesophageal reflux disease: an evaluation of continuous and on-demand therapy with rabeprazole 20 mg.
    Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 2007, Volume: 21, Issue:12

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Dose-Response Relationsh

2007
Rabeprazole versus ranitidine for the treatment of erosive gastroesophageal reflux disease: a double-blind, randomized clinical trial. Raberprazole Study Group.
    The American journal of gastroenterology, 2000, Volume: 95, Issue:8

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Antacids; Benzimidazoles; D

2000
Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis.
    Alimentary pharmacology & therapeutics, 2002, Volume: 16, Issue:3

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Esophagitis

2002
A randomized, double-blind, comparative study of standard-dose rabeprazole and high-dose omeprazole in gastro-oesophageal reflux disease.
    Alimentary pharmacology & therapeutics, 2002, Volume: 16, Issue:3

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Benzimidazoles;

2002

Other Studies

9 other studies available for rabeprazole and Pyrosis

ArticleYear
Control of acid and duodenogastroesophageal reflux (DGER) in patients with Barrett's esophagus.
    The American journal of gastroenterology, 2015, Volume: 110, Issue:8

    Topics: Aged; Barrett Esophagus; Bilirubin; Deglutition Disorders; Esophageal pH Monitoring; Female; Gastroe

2015
Characteristics of symptomatic reflux episodes in Japanese proton pump inhibitor-refractory non-erosive reflux disease patients.
    World journal of gastroenterology, 2015, Dec-21, Volume: 21, Issue:47

    Topics: Adult; Aged; Asian People; Drug Administration Schedule; Drug Resistance; Electric Impedance; Esopha

2015
Characteristics of symptomatic reflux episodes in patients with non-erosive reflux disease who have a positive symptom index on proton pump inhibitor therapy.
    Digestion, 2010, Volume: 82, Issue:3

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Esophageal pH Monitoring; Female; Gastroesopha

2010
Comparison of patients of chronic laryngitis with and without troublesome reflux symptoms.
    Journal of gastroenterology and hepatology, 2012, Volume: 27, Issue:3

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Age Factors; Anti-Ulcer Agents; Chronic Disease; End

2012
Symptoms and quality of life in underweight gastroesophageal reflux disease patients and therapeutic responses to proton pump inhibitors.
    Journal of gastroenterology and hepatology, 2012, Volume: 27, Issue:5

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Body Mass Index; Esophagitis, Pept

2012
Air swallowing can be responsible for non-response of heartburn to high-dose proton pump inhibitor.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2005, Volume: 37, Issue:6

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aerophagy; Anti-Ulcer Agents; Benzimidazoles; Dose-R

2005
A new-generation H2 receptor antagonist: quicker and stronger acid inhibition than proton pump inhibitors in the clinical setting?
    Journal of gastroenterology, 2005, Volume: 40, Issue:5

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acetamides; Benzimidazoles; Gastric Acid; Gastric Acidity D

2005
Efficacy of rabeprazole on heartburn symptom resolution in patients with non-erosive and erosive gastro-oesophageal reflux disease: a multicenter study from Japan.
    Alimentary pharmacology & therapeutics, 2007, Jul-01, Volume: 26, Issue:1

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Enzyme Inhibitors; Female;

2007
The influence of co-morbid IBS and psychological distress on outcomes and quality of life following PPI therapy in patients with gastro-oesophageal reflux disease.
    Alimentary pharmacology & therapeutics, 2008, Mar-15, Volume: 27, Issue:6

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Female; Gastroesophageal Reflux; H

2008